Skip to main content

08-06-2020 | EULAR 2020 | Conference coverage | News

News in brief

Sustained benefits with secukinumab in nonradiographic axial spondyloarthritis

Author: Lucy Piper


medwireNews: The interleukin-17A inhibitor secukinumab provides significant and sustained improvements in patients with nonradiographic axial spondyloarthritis, indicate 52-week data from the phase 3 PREVENT study.

The findings, presented by Jürgen Braun (Ruhr University Bochum, Germany) at the at the EULAR 2020 E-Congress, extend on the previously reported 16-week data showing a superior ASAS40 response rate with the treatment compared with placebo in patients naïve to tumor necrosis factor inhibitor treatment.

Patients were allowed to switch treatment any time after week 20 and 64% of placebo-treated patients and approximately 50% of secukinumab-treated patients switched to open-label secukinumab.

At 52 weeks, the ASAS40 response rates were 35.4% and 39.8% among the patients receiving secukinumab 150 mg with (n=164) and without (n=166) a loading dose, respectively, which was significantly greater than the 19.9% rate among the 171 patients receiving placebo. Braun noted that the “response was pretty consistent over time.”

Significant improvements were also seen in the secondary endpoints of BASDAI-50 response and ASDAS-CRP response, with respective rates of 30.8% and 35.3% versus 19.9%, and 15.7% and 23.9% versus 10.2%.

Braun noted that “objective signs of inflammation as assessed by the [sacroiliac] joint edema score were reduced over 52 weeks.”

He also reported that “the safety profile was very consistent with previous reports.”

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

EULAR 2020 E-Congress; 3–6 June
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-eular.598